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Novelty and Impact 
 
The incidence of prostate cancer in obese men was similar to- or slightly lower than the 
incidence in non-obese men, but obese men were diagnosed with more advanced prostate 
cancer.  Consequently, obese men with prostate cancer had higher prostate cancer specific 
mortality.  In addition to the direct effect of stage, the data are suggestive of a stage-
independent causal pathway where prostate cancer in obese men has higher fatality, even in 
early-stage disease. 
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Abstract 
There is no clear link between obesity and prostate cancer incidence but an association has 
been reported between obesity and fatal prostate cancer.  We report on two prospective 
cohort analyses on (1) the incidence of prostate cancer in relation to obesity in a cohort of 
men with no previous cancer, and on (2) the stage distribution and prostate cancer specific 
mortality in relation to obesity among men with prostate cancer. The ‘Diet, Cancer and 
Health’ prospective cohort study was established in Denmark in 1993-1997 and accrued 
26,944 men aged 50-64 years. Data were extracted on height, weight, body mass index, waist 
circumference, and body fat percentage. Information on cancer incidence and deaths were 
obtained by record linkage with the Danish Cancer Register and the Danish Death Register. 
The incidence rate of prostate cancer was similar or slightly lower in obese men compared 
with non-obese men, but obese men tended to be diagnosed with more advanced prostate 
cancer. The proportion of stage 3-4 cancers was 37% in the lowest BMI quartile and 48% in 
the highest (p=0.006). Obese men with prostate cancer had higher prostate cancer specific 
mortality. The hazard ratio comparing the highest and the lowest quartiles of body mass 
index was 1.48 (95% confidence interval: 1.06-2.05; p-value for trend: 0.002). The 
association was attenuated but not eliminated by statistical adjustment for stage, and the data 
are suggestive of a stage-independent causal pathway where prostate cancer in obese men has 
higher fatality, even in early-stage disease. 
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Introduction 
Many studies have explored the risk of prostate cancer, and its subsequent progression and 
prognosis in relation to obesity and related anthropometric measures, bioelectrical impedance 
measurements, and elements of the metabolic syndrome (1). Investigations have been carried 
out using different study designs and in populations with different ethnic composition, 
different attitudes to PSA testing and aggressiveness regarding therapy for prostate cancer. 
In the USA, positive associations were observed between body mass index (BMI), waist 
circumference (WC), body fat mass (BFM) and fat-free mass (FFM) and Gleason 7+ prostate 
cancer (2). In the European EPIC cohort, abdominal adiposity was positively associated with 
risk of advanced prostate cancer (3). A prospective cohort study in Australia found that 
weight, BMI and adult weight gain were positively associated with the risk of aggressive 
prostate cancer, but not with overall risk of prostate cancer (4). A very large cohort study in 
Sweden found a strong association between BMI and fatal prostate cancer (5). Another cohort 
study in Sweden suggested an age-specificity in the effect of BMI. High BMI in early 
adulthood was negatively associated with risk of advanced prostate cancer, whereas BMI in 
middle aged and older men was positively associated with advanced prostate cancer risk (6). 
A systematic review and meta-analysis of prospective studies showed that high BMI was 
associated with a higher risk of advanced prostate cancer (7). 
For men who underwent a radical prostatectomy, a positive association was found between 
BMI and biochemical recurrence (8). 
Apart from overweight and obesity, several studies have investigated other components of the 
metabolic syndrome in relation to risk of prostate cancer. A case-control study in Italy found 
that components of the metabolic syndrome, especially hypercholesterolemia, were 
associated with prostate cancer risk (9). The risk was four-fold higher among those with four 
components of the metabolic syndrome (obesity, hypercholesterolemia, hypertension, 
diabetes) compared to those with none. Furthermore, a Mendelian randomisation study found 
that a single-nucleotide-polymorphism in the obesity-associated FTO gene was associated 
with the risk of high grade prostate cancer (10). 
A pooled analysis of cohorts from Norway, Sweden and Austria found no higher risk of 
prostate cancer in men with the metabolic syndrome, but the risk of prostate cancer death was 
higher due to the underlying associations with BMI and high blood pressure (11). 
The Danish population has had relatively low levels of PSA testing, and is a valid context for 
the study of occurrence of symptomatic (as opposed to PSA-detected or screen-detected) 
prostate cancer (12, 13). The national cancer registration system in Denmark is of high 
quality, and can provide information about the stage of disease at the time of diagnosis. The 
registration of deaths in the population is also of high quality, and information on deaths is 
routinely added to the national cancer registry. 
The present paper describes two analyses in a prospective cohort. Firstly, we quantify the 
incidence of prostate cancer in relation to obesity in a cohort of men with no previous cancer. 
Secondly, we describe the stage distribution and quantify prostate cancer specific mortality in 
relation to obesity in the sub-cohort of men who developed prostate cancer. 
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Material and Methods 
Study population and data selection 
The present study uses the established ‘Diet, Cancer and Health’ prospective cohort study in 
Denmark (14-17). The data were collected in 1993-1997. The men were 50-64 years of age 
when included. The cohort has been described in detail elsewhere (14). 
From the data collected in the prospective study, the following exposure variables describing 
body characteristics were extracted: height, weight, BMI, waist circumference (WC), and 
body fat percentage (BFP). All were measured by trained personnel at study baseline. Height 
was measured standing without shoes and rounded to the nearest half centimeter. Weight was 
measured on a digital scale in light clothing and rounded to the nearest 100 g. Waist 
circumference was measured at the narrowest part between the lower rib and the iliac crest 
and rounded to the nearest half centimeter. Body fat percentage was measured by 
bioelectrical impedance. 
The cohort included 26,944 men. Sixty-seven men (0.2%) were excluded because data on 
body characteristics were missing, leaving 26,877 men for the present analysis. 
Information on incident cancer cases, vital status and causes of death was obtained by record 
linkage with the Danish Cancer Register and the Danish Death Register. The end-of-study 
date was December 31th 2011. 
Statistical analysis 
In the follow-up analysis for prostate cancer occurrence, the incidence of prostate cancer 
overall and advanced prostate cancer were considered in relation to the separate and joint 
effects of the five body characteristics. BMI was analysed both as conventionally categorised 
and in quartiles of its distribution. For WC, BFP and height, we used quartiles. Statistical 
analysis was pursued with Cox proportional hazards regressions with age as the underlying 
time dimension. Occurrence of prostate cancer was considered from the age at entry into the 
cohort until the age at prostate cancer diagnosis, death or end of follow-up on 31 December 
2011. For the analysis of advanced prostate cancer we considered a non-advanced prostate 
cancer as a censoring event. 
Among the prostate cancer cases that occurred within the first cohort, we considered prostate 
cancer specific deaths in relation to the five exposure variables, as above. Occurrence of 
prostate cancer deaths were considered from the age at prostate cancer diagnosis until the age 
of prostate cancer death or end of follow-up. Death from another cause than prostate cancer 
was considered as a censoring event. 
With longitudinal follow-up and censorings as described, the two time-to-event analyses are 
equivalent to cohort analyses based on enumeration of cancer occurrences and cancer deaths 
in the person-years’ experience of the cohorts, and subsequent analysis of the derived 
incidence and mortality rates.  
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Results 
The details of the cohort are summarised in Table 1. The median age at cohort entry of the 
26,877 male cohort members was 56 years and the median duration of follow-up was 15.5 
years. During the course of follow-up 1,813 men developed prostate cancer. From the date of 
diagnosis these men were followed-up for a median of 3.6 years in which 290 died from 
prostate cancer. The men who died from prostate cancer had slightly higher BMI, WC, and 
BFP as measured at the time of entry into the cohort. 
Table 2 shows the analysis of prostate cancer incidence in relation to body characteristics 
measured at the time of entry into the cohort. The incidence of prostate cancer was weakly 
inversely associated with measures of obesity. Obese men (body mass index ≥ 30 kg/m2) had 
a hazard ratio (HR) of 0.86 (95% confidence interval [CI]): 0.74-0.99). The p-value for trend 
over the three categories (-24.9; 25.0-29.9; 30.0+) was 0.03. When considering the quartile 
distributions of BMI and WC there was no statistically significant association with prostate 
cancer incidence. For BFP, there was a significant linear trend in prostate cancer incidence 
over the quartiles (p=0.018). The HR in the highest quartile vs. the lowest was 0.84 (95% CI: 
0.74-0.96). Multivariate adjustment between the obesity-related measures did not lead to any 
material change in impression of the associations. 
Height was positively associated with prostate cancer incidence (HR: 1.30 [95% CI: 1.14-
1.48]) for the highest vs lowest quartile; trend p-value over quartiles: 0.0003. The association 
with height did not change after adjustment for any of the obesity measures, and the 
associations between the obesity measures and prostate cancer incidence did not change 
materially when height was included in the regression models. 
Table 2 also shows the analysis for the risk of advanced (stage 3-4) prostate cancer (626 
cases) in relation to the measured body characteristics. Measures related to obesity were 
positively associated with risk of advanced prostate cancer (HR for the highest vs. lowest 
quartiles of BMI, WC, and BFP: 1.20 [0.97-1.50], 1.23 [0.98-1.55] and 1.31 [1.04-1.64], 
respectively). The linear trends were not statistically significant. A positive association 
between height and advanced prostate cancer was also observed. 
Table 3 shows the associations between the measured body characteristics and stage of 
prostate cancer. There were strong associations between the obesity measures (BMI; WC; 
BFP) and advanced stage of prostate cancer. The strongest of these associations was with 
BFP where 50% of prostate cancers were advanced in men in the highest quartile of BFP as 
opposed to 34% in men in the lowest quartile (chi-square for the trend over quartiles: 11.3; 
p=0.001). There was no association between height and prostate cancer stage. 
Table 4 reports the results for the analysis of prostate cancer death in relation to the measured 
body characteristics in the 1,813 men with prostate cancer. Death from prostate cancer was 
positively associated with all analysed body characteristics. Obese men (BMI ≥30) with 
prostate cancer had a HR of 1.43 (95% CI; 1.01-2.01) compared to men with low or normal 
BMI. Men with prostate cancer who were in the highest quartiles of BMI, WC and BFP had 
HRs of 1.48 (95% CI; 1.06-2.05), 1.36 (0.98-1.88), and 1.61 (1.16-2.24), respectively, 
compared to men in the lowest quartiles. The linear trends over the quartiles were statistically 
significant (p=0.02, p=0.04, and p=0.007, respectively). Additional adjustment for stage 
attenuated the associations of death from prostate cancer with BMI, WC and BFP and excess 
death rates reduced by about half. The stage adjusted HRs for BMI (30+), and upper quartiles 
of BMI, WC and BFP were 1.27 (0.90-1.80), 1.21 (0.87-1.69), 1.15 (0.83-1.60), and 1.29 
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(0.93-1.80), respectively. Stage was strongly associated with prostate cancer death, but there 
no linear association between height and prostate cancer death.  
Stage-stratified analyses of prostate cancer death in relation to the body characteristics are 
shown in Table 5. Regardless of stage category (1-2; 3; 4; n/a), there was a positive 
association between obesity related measures and prostate cancer death. In men with early 
stage prostate cancer (stage 1-2) there were positive associations between the obesity 
measures and prostate cancer death: HRs were 1.42 (0.57-3.53), 1.40 (0.59-3.36) and 1.78 
(0.72-4.41) for the highest vs. lowest quartiles of BMI, WC and BFP. 
 
Discussion 
Principal findings 
The principal findings of these analyses are: (a) The incidence of prostate cancer in obese 
men was similar to- or slightly lower than the incidence in non-obese men, but (b) obese men 
were diagnosed with more advanced prostate cancer. Consequently, (c) obese men with 
prostate cancer had higher prostate cancer specific mortality. In addition to the direct effect of 
stage, (d) the data are suggestive of a stage-independent causal pathway where prostate 
cancer in obese men has higher fatality, even for men with early-stage disease. 
The most interesting implication of these results concerns the relative importance of stage-
dependent and stage-independent mechanisms underlying the association between obesity 
and the prognosis in prostate cancer. It is evident that all the used measures (obesity; high 
BMI; high WC; high BFP) are associated with advanced stage distribution and increased 
mortality in men with prostate cancer. The strengths of these associations were sensitive to 
statistical adjustment for cancer stage which attenuated the associations. This suggests that 
the increased mortality in obese men with prostate cancer may in part be due to the adverse 
stage distribution. These data are also suggestive of a stage-independent mechanism of 
action, but it is noted that stage is not recorded in all men with prostate cancer, and it is 
inevitably collected with a degree of error. The grouping into stage categories entails a scope 
for residual confounding and bias.  We considered that in addition to the adjustment for stage 
by means of multivariate analysis, it was useful also to explore the associations within strata 
of stage. Despite the low fatality of stage 1-2 prostate cancer, there were sufficient numbers 
of men with such early stage prostate cancer, and the results are suggestive of an adverse 
effect of obesity on prognosis in men with early-stage prostate cancer.  We note that the 
stage-adjusted and the stage-stratified effects are not themselves statistically significant due 
to the attenuation of the magnitudes of effect and to the loss of statistical power in these 
analyses. 
 
Possible biological mechanisms 
 
The different measures of adiposity (BMI, WC, and BFP) are highly correlated, but describe 
different aspects of obesity. BMI is a measure of general adiposity and high WC is 
particularly indicative of abdominal adiposity. In large studies of overall mortality in the 
general population, both BMI and WC are associated with mortality in a U-shaped fashion, 
and conditionally on BMI, WC is separately and linearly associated with mortality (18). In 
the present analyses of prostate cancer specific mortality, results were similar for BMI, WC 
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and BFP, and no particular association was seen in relation to BMI-adjusted WC. This is 
possibly because the associations with prostate cancer specific mortality are only moderately 
strong and the statistical power of the cohort analysis of prostate cancer patients is limited. 
 
The adverse stage-distribution of prostate cancer in obese men may arise by different 
mechanisms. Clinically, it is more difficult to palpate the prostate in an obese man (1, 19) and 
obese men have lower PSA concentration in the blood, leading to a lower propensity for 
referral to biopsy (1, 20). Biological mechanisms have been suggested whereby obesity may 
lead to a higher growth rate of prostate tumours (21). For instance, pre-clinical evidence 
suggests that androgens stimulate prostate tumour growth via activation of pathways 
regulating lipogenic gene expression, which results in lipid accumulation (22) and crosstalk 
between androgen signaling and lipogenesis (23, 24). Castrate-resistant prostate cancer may 
synthesize androgens de novo from cholesterol and progesterone within the tumour, leading 
to androgen receptor activation independent of circulating androgens, and subsequent tumor 
growth (25, 26). Experimental evidence also suggests that fatty acid synthase (FAS) is 
involved in prostate tumorigenesis, with high expression in obese patients being associated 
with aggressive disease (27) and low survival (28). There is a growing body of literature on 
the link between prostate cancer risk and prognosis with obesity and other aspects of the 
metabolic syndrome (29, 30). Recently, it has been suggested that the effect of obesity on 
prostate cancer outcomes is especially manifest in those with the aggressive subtype of 
prostate cancer defined by TMPRSS2:ERG fusion (31). 
 
Height 
 
In addition to our findings for obesity in relation to risk and progression of prostate cancer, 
we found a positive association for height and risk of prostate cancer. However, we did not 
observe any association with stage or with disease prognosis. This pattern is in contrast with 
the findings for overweight and obesity. Results to date for the link between height and 
prostate cancer are inconsistent. A large study in Sweden found an association with height 
and incident prostate cancer, but no association with fatal prostate cancer (5). In contrast, the 
pooled EPIC cohort analysis (of which the present Danish cohort is a component) found no 
association between height and prostate cancer incidence (3). 
 
Changes in obesity over the life-course 
 
Unlike height, which does not change much over the course of the years in adulthood, 
measures of overweight and obesity may be subject to change. In the present study, 
measurements were taken at the time of entry into the cohort while aged 50-64 years and used 
to predict occurrence and fatality in the following 10-15 years. This approach is justified on 
the basis of the research question being about the typical constitutional body characteristic in 
middle-aged men and their association with disease risk thereafter. Other studies have in 
addition to the baseline measure of overweight and obesity also looked at changes in body 
weight during the life-course. Such studies reported a mixture of findings, e.g. opposite 
effects of obesity in early and late adulthood (6), weight gain being associated with increased 
prostate cancer mortality (4), and no association with either incidence or fatality (32). 
 
Strengths and limitations of the study, and implications for future research 
 
In the period of this study, the use of PSA testing in men without any symptoms was low, 
making these data less sensitive to diagnostic bias than in situations where PSA testing is 
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more frequent. In a sub-sample of the cohort it was estimated that 14% of the prostate cancer 
cases in the sample were diagnosed without any cancer-related symptoms and therefore most 
likely following a PSA test (13). 
 
Data were not available about prostate cancer treatment administered over the cause of 
follow-up.  We did not have access to data on tobacco smoking and other life-style factors 
over the course of follow-up.  
 
There is a need for large studies including detailed information on both anthropometric and 
biological measures of obesity and metabolic syndrome. The UK Biobank cohort will present 
such opportunity in a few years’ time (33). Information on stage, grade and treatment should 
ideally be available in order to resolve the question of stage-dependent and stage-independent 
mechanisms and minimise the potential for error and bias. Valid information on prostate 
cancer grade may require central review of the histopathological material (34). New 
biological markers of prognosis can be obtained from diagnostic biopsy samples (35). In the 
present era of high or increasing rate of PSA testing, new studies should include the route to 
diagnosis. 
 
The Gleason score was only available for half of the prostate cancers in the present dataset. 
We found that about 56% of the graded cancers were Gleason 7 or higher, but this proportion 
did not vary with the measures of overweight and obesity. 
 
Conclusion 
 
Obese men have a similar or slightly lower incidence rate of prostate cancer than other men, 
but with an adverse stage distribution which contributes to a higher case-fatality in obese men 
with prostate cancer. These results from a large cohort with complete follow-up and robust 
anthropological measures also suggest a worse prognosis for obese men independent of stage. 
Evidence is accumulating to support new studies with sufficient size, high data quality, and 
metabolomics and tumour information in order to resolve the roles of stage-dependent and 
stage-independent biological mechanisms. Such studies may lead to important information 
about modifiable risk factors for progression and death in men with prostate cancer. 
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Table 1. Overview of the cohort of 26,877 men and the sub-cohort of 1813 men who developed prostate cancer 
                   
  
Total cohort 
   
Sub-cohort with 
  
Prostate cancer 
 
        
prostate cancer 
  
deaths 
   
  
26877         
 
1813         
 
290         
                   Age at entry (years) Median;  
quartile 
range 56 
 
52 - 60 
 
57 
 
54 - 61 
 
59 
 
56 - 62 
Duration from entry to  
death or censoring (years) 
Median;  
quartile 
range 15.5 
 
14.8 - 16.2 
 
15.5 
 
14.8 - 16.2 
 
11.9 
 
8.2 - 14.1 
                   
Duration from prostate cancer  
diagnosis to death or censoring (years) 
Median;  
quartile 
range 
      
3.6 
 
1.9 - 6.1 
 
2.3 
 
1.1 - 4.7 
                   Body mass index, BMI, kg/m2 Mean; SD 26.6 
  
3.6 
  
26.4 
  
3.3 
  
26.9 
  
3.6 
 
                   Waist circumference, WC, cm Mean; SD 96.0 
  
10.0 
  
95.6 
  
9.5 
  
97.3 
  
10.5 
 
                   Body fat percentage, BFP Mean; SD 26.4 
  
5.4 
  
26.2 
  
5.2 
  
27.2 
  
5.3 
 
                   Height, cm Mean; SD 176.7     6.5     176.9     6.2     177.2     6.9   
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Table 2. Analysis of prostate cancer occurrence in cohort of 26,877 men 
    
      All PC cases     
 
    Stage 3-4 cases only 
Body characteristic Range 
 
#Risk #Event HR 95% conf. interval #Event HR 
95% conf. 
interval 
                  BMI: Low or Normal 15.4 - 24.9 9251 649 
 
1.00 
    
208 
 
1.00 
   BMI: Overweight 25.0 - 29.9 13486 920 
 
0.94 0.85 - 1.04 
 
314 
 
1.00 0.84 - 1.19 
BMI: Obese 30.0 - 52.7 4140 244 
 
0.86 0.74 - 0.99 
 
104 
 
1.14 0.90 - 1.44 
trend p-value 
      
0.03 
      
0.37 
   
                  BMI, kg/m2 15.4 - 24.1 6692 476 
 
1.00 
    
145 
 
1.00 
   (quartile) 24.2 - 26.1 6695 446 
 
0.90 0.79 - 1.02 
 
149 
 
0.99 0.79 - 1.24 
 
26.2 - 28.5 6795 461 
 
0.92 0.81 - 1.05 
 
156 
 
1.02 0.82 - 1.28 
 
28.6 - 52.7 6695 430 
 
0.90 0.79 - 1.02 
 
176 
 
1.20 0.97 - 1.50 
trend p-value 
      
0.14 
      
0.09 
   
                  Waist circumference, cm 56.0 - 89.0 6855 466 
 
1.00 
    
131 
 
1.00 
   (quartile) 89.5 - 95.0 6965 486 
 
0.98 0.87 - 1.12 
 
177 
 
1.27 1.02 - 1.60 
 
95.5 - 101.5 6195 430 
 
0.98 0.86 - 1.12 
 
152 
 
1.23 0.97 - 1.55 
 
102.0 - 156.0 6862 431 
 
0.90 0.79 - 1.02 
 
166 
 
1.23 0.98 - 1.55 
trend p-value 
      
0.11 
      
0.14 
   
                  Body fat percentage 1.3 - 22.8 6682 459 
 
1.00 
    
127 
 
1.00 
   (quartile) 22.9 - 26.4 6668 452 
 
0.92 0.81 - 1.05 
 
170 
 
1.25 0.99 - 1.57 
 
26.5 - 29.9 6767 471 
 
0.92 0.81 - 1.05 
 
145 
 
1.03 0.81 - 1.31 
 
30.0 - 48.4 6760 431 
 
0.84 0.74 - 0.96 
 
184 
 
1.31 1.04 - 1.64 
trend p-value 
      
0.018 
      
0.10 
   
                  Height, cm 141.5 - 172.4 6678 413 
 
1.00 
    
137 
 
1.00 
   
15 
 
(quartile) 172.5 - 176.5 6873 493 
 
1.23 1.08 - 1.40 
 
174 
 
1.31 1.05 - 1.64 
 
176.8 - 180.8 6241 432 
 
1.23 1.08 - 1.41 
 
154 
 
1.33 1.05 - 1.67 
 
181.0 - 206.0 7085 475 
 
1.30 1.14 - 1.48 
 
161 
 
1.32 1.05 - 1.66 
trend p-value             0.0003             0.02       
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Table 3. Proportions of advanced prostate cancer in relation to body characteristics 
        
 
Percent with advanced prostate cancer 
[1] in quartiles of the body 
characteristics [2] 
  
        
Body characteristic Q1 Q2 Q3 Q4   
Trend  
p-value 
 
        Body mass index 37 41 41 48 
 
0.006 
 Waist circumference, cm 35 43 44 46 
 
0.004 
 Body fat percentage 34 45 38 50 
 
0.001 
 Height, cm 40 43 43 41   0.90 
 
        [1] TNM stage 3 or 4 
       [2] Cases with unknown stage (17%) were excluded from the denominator 
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Table 4. Analysis of prostate cancer specific deaths in sub-cohort of 1813 men with prostate cancer 
            
Each adjusted 
for 
  
       
Univariate analyses 
 
stage at 
diagnosis   
 
                 
                 
Body characteristic Range   #risk #event HR 95% conf. interval HR 
95% conf. 
interval 
 
                 BMI: Low or Normal 15.4 - 24.9 649 92 
 
1.00 
    
1.00 
    BMI: Overweight 25.0 - 29.9 920 147 
 
1.08 0.83 - 1.40 
 
1.10 0.85 - 1.43 
 BMI: Obese 30.0 - 52.7 244 51 
 
1.43 1.01 - 2.01 
 
1.27 0.90 - 1.80 
 trend p-value 
      
0.07 
    
0.19 
    
                 BMI 15.4 - 24.1 476 63 
 
1.00 
    
1.00 
    (quartile) 24.2 - 26.1 446 71 
 
1.16 0.82 - 1.62 
 
1.07 0.76 - 1.50 
 
 
26.2 - 28.5 461 72 
 
1.19 0.85 - 1.67 
 
1.16 0.82 - 1.63 
 
 
28.6 - 52.7 430 84 
 
1.48 1.06 - 2.05 
 
1.21 0.87 - 1.69 
 trend p-value 
      
0.02 
    
0.22 
    
                 Waist circumference, cm 56.0 - 89.0 466 65 
 
1.00 
    
1.00 
    (quartile) 89.5 - 95.0 486 69 
 
1.02 0.72 - 1.43 
 
0.87 0.62 - 1.23 
 
 
95.5 - 101.5 430 71 
 
1.14 0.81 - 1.61 
 
1.08 0.77 - 1.53 
 
 
102.0 - 156.0 431 85 
 
1.36 0.98 - 1.88 
 
1.15 0.83 - 1.60 
 trend p-value 
      
0.04 
    
0.19 
    
                 Body fat percentage 1.3 - 22.8 459 59 
 
1.00 
    
1.00 
    (quartile) 22.9 - 26.4 452 70 
 
1.16 0.82 - 1.64 
 
0.93 0.66 - 1.33 
 
 
26.5 - 29.9 471 67 
 
1.08 0.76 - 1.54 
 
1.15 0.81 - 1.65 
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30.0 - 48.4 431 94 
 
1.61 1.16 - 2.24 
 
1.29 0.93 - 1.80 
 trend p-value 
      
0.007 
    
0.05 
    
                 Height, cm 141.5 - 172.4 413 74 
 
1.00 
    
1.00 
    (quartile) 172.5 - 176.5 493 69 
 
0.79 0.57 - 1.10 
 
0.68 0.49 - 0.94 
 
 
176.8 - 180.8 432 62 
 
0.79 0.56 - 1.11 
 
0.77 0.54 - 1.08 
 
 
181.0 - 206.0 475 85 
 
1.05 0.77 - 1.44 
 
1.04 0.76 - 1.43 
 trend p-value 
      
0.67 
    
0.51 
    
                 TNM stage 1-2 
  
871 41 
 
1.00 
         
 
3 
  
282 36 
 
3.14 2.00 - 4.91 
      
 
4 
  
344 179 
 
16.60 11.82 - 23.32 
      
 
NA 
  
316 34 
 
3.58 2.27 - 5.66 
      trend p-value [1]             <.0001                 
 
                 [1] Trend over the categories, excl. NA 
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Table 5. Analysis of prostate cancer specific deaths in sub-cohort of 1813 men with prostate cancer, stratified by stage 
     
Stage 1-2           
 
Stage 3           
 
Stage 4           
 
                             
Body characteristic Range     #risk #event HR 95% conf. interval #risk #event HR 95% conf. interval #risk #event HR 
95% conf. 
interval 
 
                             BMI: Low or Normal 15.4 - 24.9 
 
321 14 
 
1.00 
    
92 11 
 
1.00 
    
116 56 
 
1.00 
    BMI: Overweight 25.0 - 29.9 
 
446 24 
 
1.11 0.57 - 2.17 
 
147 20 
 
1.12 0.53 - 2.35 
 
167 86 
 
1.07 0.76 - 1.51 
 BMI: Obese 30.0 - 52.7 
 
104 3 
 
0.63 0.18 - 2.19 
 
43 5 
 
0.93 0.32 - 2.69 
 
61 37 
 
1.41 0.92 - 2.17 
 trend p-value 
       
0.68 
       
0.99 
       
0.15 
    
                             BMI 15.4 - 24.1 
 
243 9 
 
1.00 
    
69 8 
 
1.00 
    
76 38 
 
1.00 
    (quartile) 24.2 - 26.1 
 
215 11 
 
1.27 0.53 - 3.08 
 
66 11 
 
1.49 0.60 - 3.75 
 
83 40 
 
0.96 0.61 - 1.51 
 
 
26.2 - 28.5 
 
220 11 
 
1.29 0.53 - 3.15 
 
73 9 
 
1.20 0.46 - 3.12 
 
83 44 
 
1.15 0.74 - 1.80 
 
 
28.6 - 52.7 
 
193 10 
 
1.42 0.57 - 3.53 
 
74 8 
 
0.94 0.35 - 2.50 
 
102 57 
 
1.21 0.79 - 1.85 
 trend p-value 
       
0.47 
       
0.77 
       
0.26 
    
                             Waist circumference, 
cm 56.0 - 89.0 
 
244 9 
 
1.00 
    
63 10 
 
1.00 
    
68 35 
 
1.00 
    (quartile) 89.5 - 95.0 
 
235 9 
 
0.89 0.35 - 2.25 
 
77 6 
 
0.42 0.15 - 1.15 
 
100 48 
 
0.99 0.63 - 1.55 
 
 
95.5 - 101.5 
 
197 11 
 
1.19 0.49 - 2.90 
 
74 13 
 
0.97 0.42 - 2.23 
 
78 39 
 
1.07 0.67 - 1.70 
 
 
102.0 - 156.0 
 
195 12 
 
1.40 0.59 - 3.36 
 
68 7 
 
0.58 0.22 - 1.53 
 
98 57 
 
1.24 0.80 - 1.92 
 trend p-value 
       
0.34 
       
0.65 
       
0.25 
    
                             Body fat percentage 1.3 - 22.8 
 
243 8 
 
1.00 
    
55 6 
 
1.00 
    
72 32 
 
1.00 
    (quartile) 22.9 - 26.4 
 
205 11 
 
1.50 0.60 - 3.75 
 
72 9 
 
1.23 0.44 - 3.47 
 
98 48 
 
1.06 0.67 - 1.68 
 
 
26.5 - 29.9 
 
237 10 
 
1.12 0.44 - 2.86 
 
76 10 
 
1.42 0.51 - 3.92 
 
69 37 
 
1.29 0.79 - 2.10 
 
 
30.0 - 48.4 
 
186 12 
 
1.78 0.72 - 4.41 
 
79 11 
 
1.25 0.46 - 3.40 
 
105 62 
 
1.41 0.91 - 2.18 
 trend p-value 
       
0.33 
       
0.65 
       
0.07 
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Height, cm 141.5 - 172.4 
 
202 12 
 
1.00 
    
61 8 
 
1.00 
    
76 44 
 
1.00 
    (quartile) 172.5 - 176.5 
 
234 6 
 
0.47 0.18 - 1.26 
 
73 8 
 
0.85 0.32 - 2.28 
 
101 48 
 
0.70 0.46 - 1.06 
 
 
176.8 - 180.8 
 
203 10 
 
0.87 0.38 - 2.03 
 
69 8 
 
0.90 0.34 - 2.41 
 
85 38 
 
0.77 0.50 - 1.20 
 
 
181.0 - 206.0 
 
232 13 
 
1.05 0.48 - 2.30 
 
79 12 
 
1.12 0.45 - 2.77 
 
82 49 
 
1.01 0.66 - 1.53 
 trend p-value               0.64               0.73               0.75       
  
 
 
